Sanofi and Regeneron seek non-infringement declaration against Amgen

22-03-2017

Sanofi and Regeneron seek non-infringement declaration against Amgen

Duncan_Andison / iStockphoto.com

Sanofi and Regeneron have filed a declaratory judgment of non-infringement claiming that their product Dupixent (dupilumab) does not infringe a patent belonging to Amgen.


Sanofi, Regeneron, Amgen, non-infringement, patent, Dupixent,

LSIPR